4.6 Article

Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD

期刊

PLOS ONE
卷 17, 期 12, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0277357

关键词

-

资金

  1. Inserm
  2. Legs Poix - Chancellerie des Universites
  3. AstraZeneca
  4. Chiesi
  5. GlaxoSmithKline
  6. MedImmune LLC
  7. Novartis Pharma AG
  8. Roche

向作者/读者索取更多资源

This study investigates novel biomarkers related to clinical hallmarks of COPD using proteomic analysis. Two clusters of COPD patients were identified, with one cluster showing elevated levels of factors contributing to tissue injury, and the other cluster showing higher expression of proteins associated with enhanced immunity, host defense, cell fate, remodeling and repair, and altered metabolism/mitochondrial functions. These protein expression patterns were consistent during follow-up visits and in a limited series of COPD patients. A signature of 15 proteins accurately differentiated the two COPD clusters. This study provides insights into COPD heterogeneity and suggests the potential for targeted therapies based on specific COPD endotypes.
Objective Novel biomarkers related to main clinical hallmarks of Chronic obstructive pulmonary disease (COPD), a heterogeneous disorder with pulmonary and extra-pulmonary manifestations, were investigated by profiling the serum levels of 1305 proteins using Slow Off-rate Modified Aptamers (SOMA)scan technology. Methods Serum samples were collected from 241 COPD subjects in the multicenter French Cohort of Bronchial obstruction and Asthma to measure the expression of 1305 proteins using SOMAscan proteomic platform. Clustering of the proteomics was applied to identify disease subtypes and their functional annotation and association with key clinical parameters were examined. Cluster findings were revalidated during a follow-up visit, and compared to those obtained in a group of 47 COPD patients included in the Melbourne Longitudinal COPD Cohort. Results Unsupervised clustering identified two clusters within COPD subjects at inclusion. Cluster 1 showed elevated levels of factors contributing to tissue injury, whereas Cluster 2 had higher expression of proteins associated with enhanced immunity and host defense, cell fate, remodeling and repair and altered metabolism/mitochondrial functions. Patients in Cluster 2 had a lower incidence of exacerbations, unscheduled medical visits and prevalence of emphysema and diabetes. These protein expression patterns were conserved during a follow-up second visit, and substanciated, by a large part, in a limited series of COPD patients. Further analyses identified a signature of 15 proteins that accurately differentiated the two COPD clusters at the 2 visits. Conclusions This study provides insights into COPD heterogeneity and suggests that overexpression of factors involved in lung immunity/host defense, cell fate/repair/ remodelling and mitochondrial/metabolic activities contribute to better clinical outcomes. Hence, high throughput proteomic assay offers a powerful tool for identifying COPD endotypes and facilitating targeted therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据